查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953933

奈米顆粒契約製造服務市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、製造能力、最終用戶、地區和競爭格局分類，2021-2031年）

Nanoparticle Contract Manufacturing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Manufacturing Scale, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球奈米顆粒契約製造服務市場預計將從 2025 年的 34.2 億美元成長到 2031 年的 51.7 億美元，複合年成長率為 7.13%。

該板塊專注於奈米級遞送機制（例如脂質體和脂質奈米顆粒）的外包生產，這些機制對於藥物標靶化和提高穩定性至關重要。市場成長趨勢的主要驅動力是基因治療和腫瘤治療日益複雜，這促使製藥開發商更依賴專業的外部合作夥伴，而不是建立內部能力。產業強勁的發展勢頭進一步加劇了這種依賴性：根據美國藥品研究與製造商協會 (PhRMA) 預測，到 2024 年，將有超過 8000 種藥物進入臨床開發階段，從而持續推動對先進製造解決方案的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 34.2億美元
市場規模：2031年 51.7億美元
複合年成長率：2026-2031年 7.13%
成長最快的細分市場 脂質
最大的市場 北美洲

儘管前景樂觀，但該行業在化學、製造和品管(CMC) 合規性方面仍面臨諸多挑戰。奈米顆粒複雜的物理化學性質為實現一致的表徵和規模化生產帶來了挑戰，常常導致監管核准流程出現瓶頸。這些技術難題需要先進的分析能力，這限制了合格供應商的選擇，並增加了創新者的研發成本。因此，滿足這些嚴格的合規要求構成了一大障礙，可能會阻礙這些專業服務的快速擴張和規模化發展。

市場促進因素

基因治療和mRNA研發管線的快速發展是全球奈米顆粒契約製造服務市場的主要驅動力。隨著這些先進治療方法從研究階段邁向商業化，對確保有效細胞內遞送的脂質奈米顆粒（LNP）的需求迅速成長，相應的，對專業化生產能力的需求也隨之增加。這一趨勢得到了大量資本投資的支持；截至2025年12月，再生醫學聯盟報告稱，2024年細胞和基因治療領域的投資額達到152億美元。如此強勁的資本支持正在推動各種需要高品質奈米製劑的臨床研究。贏創公司在2025年9月預測，到2032年，脂質奈米顆粒市場規模將達到23億美元，進一步凸顯了其長期商業性潛力。

同時，複雜奈米顆粒製劑外包的趨勢日益成長，從根本上改變了市場結構。聚合物和脂質奈米顆粒的合成涉及複雜的物理化學過程，需要精確控制其穩定性和粒徑，而這些專業技術對於製藥創新企業而言往往過於耗費資源，難以在內部維持。因此，企業通常選擇與合約研發生產機構 (CDMO) 合作，以利用其監管知識和專業基礎設施。領先供應商強勁的財務業績也印證了這種向外部生產轉變的成功。據 Reseepharm 公司稱，該公司於 2025 年 3 月宣布，2024 會計年度銷售額創下 8.27 億歐元的紀錄，較上年成長 7%，這主要得益於對綜合生產和研發服務的持續需求。

市場挑戰

嚴格的化學、製造和控制 (CMC) 法規對奈米顆粒的生產構成重大障礙，阻礙了全球奈米顆粒契約製造服務市場的擴張。奈米顆粒具有複雜的物理化學性質，例如表面電荷、粒徑分佈和包封率，這些性質在從實驗室規模原型過渡到商業化批量生產時極難控制。這種不可預測性導致生產過程中的變異性，使得合約研發生產機構 (CDMO) 難以滿足監管機構要求的嚴格品質標準，從而導致產品上市延遲。

因此，這些技術執行上的失敗會導致研發週期延長，在開發產品的失敗率更高。由於缺乏表徵數據而導致的計劃延期和被拒，使創新者面臨巨大的財務風險，並大幅減少了能夠轉化為盈利商業生產合約的可行專案數量。近期產業數據也印證了這一嚴峻情況：根據生物技術與創新組織（BIO）的數據顯示，2024年在臨床實驗藥物的臨床開發成功率降至歷史新低，僅6.7%。這一下降主要歸因於現代治療方法的日益複雜化。如此高的失敗率嚴重限制了可用於外包生產的已已通過核准產品的供應，阻礙了其快速市場擴充性。

市場趨勢

隨著製藥公司尋求簡化複雜的供應鏈，整合、端到端的CDMO服務模式的轉變正在改變市場格局。傳統上，脂質奈米顆粒的生產需要與多家供應商協調，分別負責活性成分的生產、脂質合成、顆粒組裝以及填充和包裝，這導致技術轉移延遲和物流風險。為了應對這些挑戰，服務供應商正在提供整合這些關鍵流程的綜合解決方案，從而有效縮短先進療法的研發週期。這些業務部門的顯著財務規模也反映了向全面服務整合的策略轉變。根據龍沙集團於2025年5月發布的“2024年更新比較財務業績”，其涵蓋端到端模式的一體化生物製劑平台預計將創造28.8億瑞士法郎的銷售額，凸顯了市場對一體化生產合作夥伴的強勁需求。

同時，為滿足日益增加的複雜生物藥物研發管線的需求，無機和聚合物奈米載體系統的產能擴張正在加速。隨著mRNA疫苗和基因療法的臨床應用不斷擴展，契約製造正大力投資於專用基礎設施，以實現這些先進遞送載體的大規模生產。這些資本投資旨在增強技術能力和物理產能，以應對下一代奈米藥物複雜的物理化學要求。這一趨勢在近期的基礎設施建設中得到了充分體現。在CordenPharma於2025年10月發表的一篇題為「CDMO主要平台投資」的報導中，該公司詳細介紹了其設施擴建計劃，計劃新增約900平方公尺符合GMP標準的生產空間，專門用於生產脂質奈米顆粒和其他非病毒載體。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球奈米顆粒契約製造服務市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（脂質、金屬、其他）
    • 依用途（治療藥物、診斷藥物等）
    • 依生產規模（臨床前、臨床、商業化）
    • 依最終用戶（製藥/生技公司、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美奈米顆粒契約製造服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲奈米顆粒契約製造服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區奈米顆粒契約製造服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲奈米顆粒契約製造服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲奈米顆粒契約製造服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球奈米顆粒契約製造服務市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Catalent
  • Lonza
  • Evonik
  • Particle Sciences
  • Precision NanoSystems
  • CordenPharma
  • WuXi AppTec
  • Novasep
  • Formulaction
  • Curia

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26731

The Global Nanoparticle Contract Manufacturing Services Market is projected to expand from USD 3.42 Billion in 2025 to USD 5.17 Billion by 2031, reflecting a CAGR of 7.13%. This sector focuses on the outsourced creation of nanoscale delivery mechanisms, including liposomes and lipid nanoparticles, which are essential for improving drug targeting and stability. The market's upward momentum is largely fueled by the growing intricacy of gene therapy and oncology treatments, which prompts pharmaceutical developers to rely on the specialized facilities of external partners rather than building internal capabilities. This dependency is highlighted by significant industry momentum; according to PhRMA, more than 8,000 medicines were in clinical development during 2024, generating continuous demand for sophisticated manufacturing solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.42 Billion
Market Size 2031USD 5.17 Billion
CAGR 2026-20317.13%
Fastest Growing SegmentLipid
Largest MarketNorth America

Despite this favorable outlook, the industry faces substantial hurdles related to Chemistry, Manufacturing, and Controls (CMC) compliance. The intricate physicochemical nature of nanoparticles creates challenges in achieving consistent characterization and scale-up, frequently leading to bottlenecks in the regulatory approval timeline. These technical difficulties require advanced analytical capabilities, which limits the pool of qualified vendors and drives up development expenses for innovators. As a result, meeting these stringent compliance requirements stands as a critical barrier that could potentially hinder the rapid expansion and scalability of these specialized services.

Market Driver

The surging growth of gene therapy and mRNA pipelines acts as a major engine for the Global Nanoparticle Contract Manufacturing Services Market. As these cutting-edge modalities progress from research phases to commercialization, the necessity for lipid nanoparticles (LNPs) to ensure effective intracellular delivery has escalated, triggering a simultaneous rise in the need for specialized manufacturing capabilities. This trend is supported by substantial financial investment; the Alliance for Regenerative Medicine reported that investments in the cell and gene therapy sector reached $15.2 billion for the year 2024 as of December 2025. Such strong capital support fuels a wide range of clinical initiatives requiring premium nanoscale formulations, with long-term commercial promise further emphasized by Evonik's September 2025 estimate that the lipid nanoparticle market will hit US$2.3 billion by 2032.

Simultaneously, the increasing tendency to outsource complex nanoparticle formulations is fundamentally altering market mechanics. Synthesizing polymeric and lipid nanoparticles involves elaborate physicochemical procedures demanding exact control over stability and particle size, competencies that are often too resource-heavy for pharmaceutical innovators to sustain internally. Consequently, organizations are frequently allying with Contract Development and Manufacturing Organizations (CDMOs) to utilize their regulatory knowledge and specialized infrastructure. The success of this shift toward external production is demonstrated by the robust financial results of top providers; according to Recipharm, the company announced a record revenue of €827 million for 2024 in March 2025, marking a 7% annual increase fueled by sustained demand for its comprehensive manufacturing and development services.

Market Challenge

Strict Chemistry, Manufacturing, and Controls (CMC) regulations overseeing nanoparticle production represent a significant obstacle to the Global Nanoparticle Contract Manufacturing Services Market's expansion. Nanoparticles exhibit complex physicochemical properties-such as surface charge, size distribution, and encapsulation efficiency-that are exceptionally hard to regulate when moving from lab-scale prototypes to commercial batches. This lack of predictability often results in manufacturing variations, making it difficult for CDMOs to adhere to the rigorous quality benchmarks mandated by regulatory agencies, which in turn stalls product release.

As a result, these failures in technical execution lead to prolonged development schedules and higher failure rates for pipeline assets. Innovators encounter considerable financial jeopardy as projects suffer delays or rejections stemming from insufficient characterization data, effectively shrinking the number of viable programs that graduate to profitable commercial manufacturing agreements. This arduous landscape is highlighted by recent industry data; according to the Biotechnology Innovation Organization, the overall clinical development success rate for investigational drugs fell to a historic low of just 6.7% in 2024, a decline largely attributed to the growing complexity of modern therapies. Such elevated attrition rates critically restrict the supply of approved products ready for outsourced production, thereby obstructing the market's rapid scalability.

Market Trends

The shift toward Integrated End-to-End CDMO Service Models is transforming the market landscape as pharmaceutical companies increasingly look to simplify complex supply chains. Traditionally, producing lipid nanoparticles involved coordinating with various vendors for payload manufacturing, lipid synthesis, particle assembly, and fill-finish, a process that created significant technical transfer delays and logistical liabilities. In response, service providers are combining these essential stages into unified offerings, effectively accelerating development timelines for advanced therapeutics. The strategic move toward holistic service integration is evidenced by the massive financial scale of these divisions; according to Lonza Group's 'Updated Comparative Financial Results for 2024' released in May 2025, their Integrated Biologics platform, covering end-to-end modalities, recorded sales of CHF 2.88 billion, highlighting the strong demand for consolidated manufacturing partners.

At the same time, the expansion of capabilities for inorganic and polymeric nanocarrier systems is speeding up to meet the growing pipeline of complex biologic drugs. As the clinical use of mRNA vaccines and gene therapies broadens, contract manufacturers are heavily investing in specialized infrastructure to facilitate the high-volume production of these sophisticated delivery vectors. These capital injections are aimed at boosting technical competencies and physical capacity to manage the complex physicochemical demands of next-generation nanomedicines. This trend is illustrated by recent infrastructure upgrades; according to a CordenPharma article titled 'CDMO Key Platform Investment' from October 2025, the firm detailed a facility expansion adding roughly 900 square meters of GMP-compliant space specifically for manufacturing lipid nanoparticles and other non-viral vectors.

Key Market Players

  • Catalent
  • Lonza
  • Evonik
  • Particle Sciences
  • Precision NanoSystems
  • CordenPharma
  • WuXi AppTec
  • Novasep
  • Formulaction
  • Curia

Report Scope

In this report, the Global Nanoparticle Contract Manufacturing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanoparticle Contract Manufacturing Services Market, By Type

  • Lipid
  • Metal
  • Others

Nanoparticle Contract Manufacturing Services Market, By Application

  • Therapeutics
  • Diagnostics
  • Others

Nanoparticle Contract Manufacturing Services Market, By Manufacturing Scale

  • Pre-clinical
  • Clinical
  • Commercial

Nanoparticle Contract Manufacturing Services Market, By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

Nanoparticle Contract Manufacturing Services Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nanoparticle Contract Manufacturing Services Market.

Available Customizations:

Global Nanoparticle Contract Manufacturing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanoparticle Contract Manufacturing Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Lipid, Metal, Others)
    • 5.2.2. By Application (Therapeutics, Diagnostics, Others)
    • 5.2.3. By Manufacturing Scale (Pre-clinical, Clinical, Commercial)
    • 5.2.4. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Nanoparticle Contract Manufacturing Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Manufacturing Scale
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nanoparticle Contract Manufacturing Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Manufacturing Scale
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Nanoparticle Contract Manufacturing Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Manufacturing Scale
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Nanoparticle Contract Manufacturing Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Manufacturing Scale
        • 6.3.3.2.4. By End User

7. Europe Nanoparticle Contract Manufacturing Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Manufacturing Scale
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nanoparticle Contract Manufacturing Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Manufacturing Scale
        • 7.3.1.2.4. By End User
    • 7.3.2. France Nanoparticle Contract Manufacturing Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Manufacturing Scale
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Nanoparticle Contract Manufacturing Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Manufacturing Scale
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Nanoparticle Contract Manufacturing Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Manufacturing Scale
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Nanoparticle Contract Manufacturing Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Manufacturing Scale
        • 7.3.5.2.4. By End User

8. Asia Pacific Nanoparticle Contract Manufacturing Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Manufacturing Scale
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nanoparticle Contract Manufacturing Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Manufacturing Scale
        • 8.3.1.2.4. By End User
    • 8.3.2. India Nanoparticle Contract Manufacturing Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Manufacturing Scale
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Nanoparticle Contract Manufacturing Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Manufacturing Scale
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Nanoparticle Contract Manufacturing Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Manufacturing Scale
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Nanoparticle Contract Manufacturing Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Manufacturing Scale
        • 8.3.5.2.4. By End User

9. Middle East & Africa Nanoparticle Contract Manufacturing Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Manufacturing Scale
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nanoparticle Contract Manufacturing Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Manufacturing Scale
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Nanoparticle Contract Manufacturing Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Manufacturing Scale
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Nanoparticle Contract Manufacturing Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Manufacturing Scale
        • 9.3.3.2.4. By End User

10. South America Nanoparticle Contract Manufacturing Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Manufacturing Scale
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nanoparticle Contract Manufacturing Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Manufacturing Scale
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Nanoparticle Contract Manufacturing Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Manufacturing Scale
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Nanoparticle Contract Manufacturing Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Manufacturing Scale
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nanoparticle Contract Manufacturing Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Catalent
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza
  • 15.3. Evonik
  • 15.4. Particle Sciences
  • 15.5. Precision NanoSystems
  • 15.6. CordenPharma
  • 15.7. WuXi AppTec
  • 15.8. Novasep
  • 15.9. Formulaction
  • 15.10. Curia

16. Strategic Recommendations

17. About Us & Disclaimer